A7165
1,5-脱水- D -山梨醇
crystalline, ≥98.0% (TLC)
别名:
1,5-脱水- D -葡糖醇
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C6H12O5
化学文摘社编号:
分子量:
164.16
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12352201
EC Number:
205-829-3
MDL number:
InChI key
MPCAJMNYNOGXPB-UHFFFAOYSA-N
InChI
1S/C6H12O5/c7-1-4-6(10)5(9)3(8)2-11-4/h3-10H,1-2H2
SMILES string
OCC1OCC(O)C(O)C1O
assay
≥98.0% (TLC)
form
crystalline
color
white
solubility
water: 49.00-51.00 mg/mL, clear, colorless
Quality Level
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Lingzi Li et al.
Diabetes, 68(12), 2272-2286 (2019-09-21)
Identification of individuals with decreased functional β-cell mass is essential for the prevention of diabetes. However, in vivo detection of early asymptomatic β-cell defect remains unsuccessful. Metabolomics has emerged as a powerful tool in providing readouts of early disease states
Stephen P Juraschek et al.
Clinical chemistry, 58(12), 1648-1655 (2012-09-29)
1,5-Anhydroglucitol (1,5-AG), fructosamine, and glycated albumin are of increasing interest as alternative measures of hyperglycemia. We characterize the associations of these nontraditional glycemic markers with hemoglobin A(1c) (Hb A(1c)) and fasting glucose and assess their ability to identify people with
Nobuya Inagaki et al.
The lancet. Diabetes & endocrinology, 3(3), 191-197 (2015-01-23)
Trelagliptin is a novel once-weekly oral DPP-4 inhibitor. We assessed the efficacy and safety of trelagliptin versus the daily oral DPP-4 inhibitor alogliptin in Japanese patients with type 2 diabetes. We did a randomised, double-blind, active-controlled, parallel-group, phase 3, non-inferiority
Roy Beck et al.
Pediatric diabetes, 12(8), 690-695 (2011-04-19)
To describe the interrelationships of glycemic control measures: hemoglobin A1c (HbA1c), glycated albumin, fructosamine, 1,5-anhydroglucitrol (1,5-AG), and continuous glucose monitoring (CGM) in children and adolescents with type 1 diabetes. In total, 26 subjects of age 4-17 had HbA1c measurement followed
Masaya Sakamoto et al.
Cardiovascular diabetology, 11, 92-92 (2012-08-08)
No previous studies have compared the DPP-4 inhibitors vildagliptin and sitagliptin in terms of blood glucose levels using continuous glucose monitoring (CGM) and cardiovascular parameters. Twenty patients with type 2 diabetes mellitus were randomly allocated to groups who received vildagliptin
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持